Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M. Syeda(NYU Langone Health), David Polsky(New York University), James E. Garrett, Jan C. Brase(Novartis (Switzerland)), Keith T. Flaherty(Cancer Research Center), Dirk Schadendorf(National Center for Tumor Diseases), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Jean‐Jacques Grob(Aix-Marseille Université), Eduard Gasal, Georgina V. Long(The University of Sydney), Antoni Ribas(University of California, Los Angeles), Paul Nathan(Mount Vernon Hospital), Caroline Robert(Institut Gustave Roussy), Matthew Squires(Novartis (United States)), Jennifer Wiggins(New York University), Mahtab Marker(Novartis (United States)), Broderick C. Corless(Cornell University)
Cited by 96
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k